Management team

Eric Rougemond, M.D.
Chief Executive Officer
Eric Rougemond, currently CEO of Laboratoire Aguettant, was appointed CEO of PX'Therapeutics in June 2013. Eric is a Doctor of Medicine, specialised in Clinical Biology. He was formerly the General Manager (France) and VP of EUSA Pharma. Prior to taking up his position at PX'Therapeutics, he served as Medical Director at Merck KGaA and OPi. Eric brings to PX'Therapeutics extensive experience in the life-sciences industry and the ambition to strengthen PX'Therapeutics’ position as one of the leading European mid-size Contract Development and Manufacturing Organisations.

Claire Untereiner
Chief Operating Officer
Claire Untereiner joined PXT in January 2008 as Business Development Manager and moved to the position of Business Development and Marketing Director in January 2011. In the past, Claire held marketing and project-management positions in the health and life-sciences sectors. She holds a Master’s degree in Biochemistry from the University of Lyon and a Master’s degree in Technology & Innovation Management from the EM LYON Business School. She is responsible for the day-to-day running of the various departments within the company as well as business development.

Fabrice Gurliat
Quality Director - Qualified Person                                                                                                                                 With a PhD in Pharmacy and a Master’s Degree in Industrial Pharmacy, Fabrice is highly experienced in Quality Management, having worked for many years in different life sciences companies. He is joining PX’Therapeutics with working experience in GxPs and a change management track record. Fabrice will bring his experience in sterile drug manufacturing gain in a large pharmaceutical company to lead our customer project to successful registration. With his past experience in analytical method development and a track record in QC activities improvements, he will contribute to the growth of our product characterization offer. Previously working as a senior consultant especially for biotech companies, he will emphasize Quality Risk Management at PX’Therapeutics and support development projects evolving to Quality by Design principles.